JPH0149328B2 - - Google Patents

Info

Publication number
JPH0149328B2
JPH0149328B2 JP60278106A JP27810685A JPH0149328B2 JP H0149328 B2 JPH0149328 B2 JP H0149328B2 JP 60278106 A JP60278106 A JP 60278106A JP 27810685 A JP27810685 A JP 27810685A JP H0149328 B2 JPH0149328 B2 JP H0149328B2
Authority
JP
Japan
Prior art keywords
mmol
cysteine
urine
phosphate
serum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP60278106A
Other languages
English (en)
Japanese (ja)
Other versions
JPS61140522A (ja
Inventor
Hans Joachim Dulce
Werner Stumpf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Madaus Holding GmbH
Original Assignee
Dr Madaus GmbH and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Madaus GmbH and Co filed Critical Dr Madaus GmbH and Co
Publication of JPS61140522A publication Critical patent/JPS61140522A/ja
Publication of JPH0149328B2 publication Critical patent/JPH0149328B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP60278106A 1984-12-12 1985-12-12 腎ぞう病‐泌尿器科用医薬 Granted JPS61140522A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3445253.2 1984-12-12
DE3445253A DE3445253A1 (de) 1984-12-12 1984-12-12 Nephrologisch-urologisches arzneimittel

Publications (2)

Publication Number Publication Date
JPS61140522A JPS61140522A (ja) 1986-06-27
JPH0149328B2 true JPH0149328B2 (enExample) 1989-10-24

Family

ID=6252540

Family Applications (1)

Application Number Title Priority Date Filing Date
JP60278106A Granted JPS61140522A (ja) 1984-12-12 1985-12-12 腎ぞう病‐泌尿器科用医薬

Country Status (5)

Country Link
US (1) US4849452A (enExample)
JP (1) JPS61140522A (enExample)
CA (1) CA1263603A (enExample)
CH (1) CH665773A5 (enExample)
DE (1) DE3445253A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3445253A1 (de) * 1984-12-12 1986-06-26 Dr. Madaus & Co, 5000 Köln Nephrologisch-urologisches arzneimittel
GB2245491A (en) * 1990-06-25 1992-01-08 Medvet Science Pty Ltd Inhibition of metabolic oxalate formation
US6764693B1 (en) 1992-12-11 2004-07-20 Amaox, Ltd. Free radical quenching composition and a method to increase intracellular and/or extracellular antioxidants
ITMI20032528A1 (it) * 2003-12-19 2005-06-20 Francesco Santangelo Uso di cistina o di cisteina per la prevenzione e il
US8148356B2 (en) 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
ES2486441B1 (es) * 2014-04-02 2015-06-11 Universitat De Les Illes Balears Preparaciones combinadas de acidificantes urinarios e inhibidores de la cristalización y su aplicación para el tratamiento o prevención de la litiasis renal fosfática o inducida por fosfato cálcico

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4378351A (en) * 1980-07-11 1983-03-29 Vojislav Petrovich Methods of treating bacterial, viral or parasitic diseases
IT1195288B (it) * 1981-11-05 1988-10-12 Zambeletti Spa L Composizione farmaceutica per la terapia di calcolosi renale infetta
FR2521429B1 (fr) * 1982-02-15 1988-10-28 Mayoly Spindler Laboratoires Nouvelles compositions a effet antiasthenique puissant a base de sels doubles de l'acide ascorbique et d'un diacide amine
US4721705A (en) * 1983-09-26 1988-01-26 Chemish Adviesbureau Drs. J.C.P. Schreuder B.V. Skin treatment compositions
DE3445253A1 (de) * 1984-12-12 1986-06-26 Dr. Madaus & Co, 5000 Köln Nephrologisch-urologisches arzneimittel

Also Published As

Publication number Publication date
DE3445253A1 (de) 1986-06-26
CH665773A5 (de) 1988-06-15
US4849452A (en) 1989-07-18
CA1263603A (en) 1989-12-05
DE3445253C2 (enExample) 1991-09-26
JPS61140522A (ja) 1986-06-27

Similar Documents

Publication Publication Date Title
Mahaffey Nutritional factors and susceptibility to lead toxicity
Schwartz et al. On the mechanism of acidosis in chronic renal disease
Goff et al. Relative acidifying activity of anionic salts commonly used to prevent milk fever
Slatopolsky et al. On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog
LLACH et al. On the mechanism of secondary hyperparathyroidism in moderate renal insufficiency
Perez et al. Safety and efficacy of oral calcitriol (1, 25‐dihydroxyvitamin D3) for the treatment of psoriasis
Bushinsky Nephrolithiasis.
Pak Citrate and renal calculi: new insights and future directions
US5753706A (en) Methods for treating renal failure
Michelis et al. Decreased bicarbonate threshold and renal magnesium wasting in a sibship with distal renal tubular acidosis: Evaluation of the pathophysiologic role of parathyroid hormone
Balsan et al. Linear growth in patients with hypophosphatemic vitamin D-resistant rickets: influence of treatment regimen and parental height
JP5419298B2 (ja) 骨粗鬆症の予防及び回復のためのカルシウム、マグネシウム、亜鉛、ビタミンｄ３を含む調剤
Kamel et al. Prolonged total fasting: a feast for the integrative physiologist
Santos et al. Hypercalciuria associated with long-term administration of calcitriol (1, 25-dihydroxyvitamin D3): action of hydrochlorothiazide
Lau et al. Differing effects of acid versus neutral phosphate therapy of hypercalciuria
Greenman et al. Biochemical disturbances and clinical symptoms during prolonged exchange resin therapy in congestive heart failure
US4849452A (en) Nephro-urological medicament
Hess et al. Relative hypoparathyroidism and calcitriol up-regulation in hypercalciuric calcium renal stone formers–impact of nutrition
Lennon Metabolic Acidosis: A Factor in the Pathogenesis of Azotemic Osteodystrophy?
Slatopolsky et al. Alternative phosphate binders in dialysis patients: calcium carbonate
Schwille et al. Citrate and recurrent idiopathic calcium urolithiasis: a longitudinal pilot study on the metabolic effects of oral potassium citrate administered over the short-, medium-and long-term medication of male stone patients
Snodgrass et al. Selenium: Childhood poisoning and cystic fibrosis
RU2527042C1 (ru) Биологически активная добавка к пище для профилактики заболеваний остеопорозом
Pizzarelli et al. Effect of chronic administration of ammonium sulfate on phosphatic stone recurrence
Nunan et al. Intestinal calcium absorption in patients after jejuno-ileal bypass or small intestinal resection and the effect of vitamin D